CONTINUOUS SINGLE-RATE LONG-TERM INSULIN INFUSION USING A TOTALLY IMPLANTABLE PUMP.

E. P. Chute; W. M. Rupp; T. D. Rohde; F. J. Goldenberg; P. H. Bordewich; C. R. Hitchcock; P. J. Blackshear; H. Buchwald

CONTINUOUS SINGLE-RATE LONG-TERM INSULIN INFUSION USING A TOTALLY IMPLANTABLE PUMP.

E. P. Chute, W. M. Rupp, T. D. Rohde, F. J. Goldenberg, P. H. Bordewich, C. R. Hitchcock, P. J. Blackshear, H. Buchwald

Surgery

Research output: Contribution to journal › Conference article › peer-review

1 Scopus citations

Abstract

Since 1980 the totally implantable insulin pump has been used to deliver insulin to Type I and Type II diabetic patients. A group of 30 patients has continued to use and enjoy the benefits of this pump (Infusaid Model 100). Pump safety and reliability have been excellent. The pump has functioned for 458 patient-months in this group of diabetic patients. Complications consist of one pump pocket infection, a pump plugging shortly after placement, and one pump replacement for gradual flow decrease. All pump insulin flow has been continuous and single-rate; most, but not all, of the Type I patients supplement with subcutaneous insulin, none of the Type II patients supplement. Hypoglycemia has been rare, mild, and not requiring medical attention. Hyperglycemia has been largely prevented.

Original language	English (US)
Pages (from-to)	387-389
Number of pages	3
Journal	Transactions - American Society for Artificial Internal Organs
Volume	30
State	Published - Dec 1 1984

OpenUrl availability

Full text

Cite this

@article{42550ffe2886493b828ac5acb6cad8f0,

title = "CONTINUOUS SINGLE-RATE LONG-TERM INSULIN INFUSION USING A TOTALLY IMPLANTABLE PUMP.",

abstract = "Since 1980 the totally implantable insulin pump has been used to deliver insulin to Type I and Type II diabetic patients. A group of 30 patients has continued to use and enjoy the benefits of this pump (Infusaid Model 100). Pump safety and reliability have been excellent. The pump has functioned for 458 patient-months in this group of diabetic patients. Complications consist of one pump pocket infection, a pump plugging shortly after placement, and one pump replacement for gradual flow decrease. All pump insulin flow has been continuous and single-rate; most, but not all, of the Type I patients supplement with subcutaneous insulin, none of the Type II patients supplement. Hypoglycemia has been rare, mild, and not requiring medical attention. Hyperglycemia has been largely prevented.",

author = "Chute, {E. P.} and Rupp, {W. M.} and Rohde, {T. D.} and Goldenberg, {F. J.} and Bordewich, {P. H.} and Hitchcock, {C. R.} and Blackshear, {P. J.} and H. Buchwald",

year = "1984",

month = dec,

day = "1",

language = "English (US)",

volume = "30",

pages = "387--389",

journal = "Transactions - American Society for Artificial Internal Organs",

issn = "0066-0078",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - CONTINUOUS SINGLE-RATE LONG-TERM INSULIN INFUSION USING A TOTALLY IMPLANTABLE PUMP.

AU - Chute, E. P.

AU - Rupp, W. M.

AU - Rohde, T. D.

AU - Goldenberg, F. J.

AU - Bordewich, P. H.

AU - Hitchcock, C. R.

AU - Blackshear, P. J.

AU - Buchwald, H.

PY - 1984/12/1

Y1 - 1984/12/1

N2 - Since 1980 the totally implantable insulin pump has been used to deliver insulin to Type I and Type II diabetic patients. A group of 30 patients has continued to use and enjoy the benefits of this pump (Infusaid Model 100). Pump safety and reliability have been excellent. The pump has functioned for 458 patient-months in this group of diabetic patients. Complications consist of one pump pocket infection, a pump plugging shortly after placement, and one pump replacement for gradual flow decrease. All pump insulin flow has been continuous and single-rate; most, but not all, of the Type I patients supplement with subcutaneous insulin, none of the Type II patients supplement. Hypoglycemia has been rare, mild, and not requiring medical attention. Hyperglycemia has been largely prevented.

AB - Since 1980 the totally implantable insulin pump has been used to deliver insulin to Type I and Type II diabetic patients. A group of 30 patients has continued to use and enjoy the benefits of this pump (Infusaid Model 100). Pump safety and reliability have been excellent. The pump has functioned for 458 patient-months in this group of diabetic patients. Complications consist of one pump pocket infection, a pump plugging shortly after placement, and one pump replacement for gradual flow decrease. All pump insulin flow has been continuous and single-rate; most, but not all, of the Type I patients supplement with subcutaneous insulin, none of the Type II patients supplement. Hypoglycemia has been rare, mild, and not requiring medical attention. Hyperglycemia has been largely prevented.

UR - http://www.scopus.com/inward/record.url?scp=0021645530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021645530&partnerID=8YFLogxK

M3 - Conference article

C2 - 6533912

AN - SCOPUS:0021645530

SN - 0066-0078

VL - 30

SP - 387

EP - 389

JO - Transactions - American Society for Artificial Internal Organs

JF - Transactions - American Society for Artificial Internal Organs

ER -

CONTINUOUS SINGLE-RATE LONG-TERM INSULIN INFUSION USING A TOTALLY IMPLANTABLE PUMP.

Abstract

OpenUrl availability

Other files and links

Fingerprint

Cite this